Biomarkers of cancer-associated thromboembolism

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Venous thromboembolism is known to be associated with an increase in morbidity and mortality in patients with malignancy. Predictive laboratory biomarkers of venous thromboembolism (VTE) have long been sought after to improve outcomes and help guide clinical decision making. Previously studied biomarkers include C reactive protein (CRP), tissue factor expressing microparticles (TF MP), D-dimer, soluble P-selectin (sP-selectin), plasminogen activator inhibitor 1 (PAI-1), factor VIII, platelet count, and leukocyte counts. This chapter will focus on these possible biomarkers for cancer-associated thrombosis (CAT) with particular emphasis on the pathophysiology behind thrombosis formation as well as data from clinical studies in patients with malignancy. The incorporation of the above biomarkers into risk assessment tools to predict CAT will also be reviewed, as will risk factors for recurrent VTE in patients with malignancy. Further studies are ongoing to develop readily available biomarkers that can be incorporated into future risk assessment models with the goal of reducing morbidity and mortality due to cancer-associated thrombosis.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages69-85
Number of pages17
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume179
ISSN (Print)0927-3042

Fingerprint

Thromboembolism
Tumor Biomarkers
Venous Thromboembolism
Thrombosis
Biomarkers
Neoplasms
Morbidity
P-Selectin
Mortality
Plasminogen Activator Inhibitor 1
Factor VIII
Thromboplastin
Platelet Count
Leukocyte Count
C-Reactive Protein

Keywords

  • Biomarkers
  • C reactive protein
  • D-dimer
  • Factor VIII
  • P-selectin
  • Tissue factor
  • Venous thrombosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mahajan, A., & Wun, T. (2019). Biomarkers of cancer-associated thromboembolism. In Cancer Treatment and Research (pp. 69-85). (Cancer Treatment and Research; Vol. 179). Springer International Publishing. https://doi.org/10.1007/978-3-030-20315-3_5

Biomarkers of cancer-associated thromboembolism. / Mahajan, Anjlee; Wun, Theodore.

Cancer Treatment and Research. Springer International Publishing, 2019. p. 69-85 (Cancer Treatment and Research; Vol. 179).

Research output: Chapter in Book/Report/Conference proceedingChapter

Mahajan, A & Wun, T 2019, Biomarkers of cancer-associated thromboembolism. in Cancer Treatment and Research. Cancer Treatment and Research, vol. 179, Springer International Publishing, pp. 69-85. https://doi.org/10.1007/978-3-030-20315-3_5
Mahajan A, Wun T. Biomarkers of cancer-associated thromboembolism. In Cancer Treatment and Research. Springer International Publishing. 2019. p. 69-85. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-030-20315-3_5
Mahajan, Anjlee ; Wun, Theodore. / Biomarkers of cancer-associated thromboembolism. Cancer Treatment and Research. Springer International Publishing, 2019. pp. 69-85 (Cancer Treatment and Research).
@inbook{18c72456b94c49a7924e9b807a339386,
title = "Biomarkers of cancer-associated thromboembolism",
abstract = "Venous thromboembolism is known to be associated with an increase in morbidity and mortality in patients with malignancy. Predictive laboratory biomarkers of venous thromboembolism (VTE) have long been sought after to improve outcomes and help guide clinical decision making. Previously studied biomarkers include C reactive protein (CRP), tissue factor expressing microparticles (TF MP), D-dimer, soluble P-selectin (sP-selectin), plasminogen activator inhibitor 1 (PAI-1), factor VIII, platelet count, and leukocyte counts. This chapter will focus on these possible biomarkers for cancer-associated thrombosis (CAT) with particular emphasis on the pathophysiology behind thrombosis formation as well as data from clinical studies in patients with malignancy. The incorporation of the above biomarkers into risk assessment tools to predict CAT will also be reviewed, as will risk factors for recurrent VTE in patients with malignancy. Further studies are ongoing to develop readily available biomarkers that can be incorporated into future risk assessment models with the goal of reducing morbidity and mortality due to cancer-associated thrombosis.",
keywords = "Biomarkers, C reactive protein, D-dimer, Factor VIII, P-selectin, Tissue factor, Venous thrombosis",
author = "Anjlee Mahajan and Theodore Wun",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-3-030-20315-3_5",
language = "English (US)",
series = "Cancer Treatment and Research",
publisher = "Springer International Publishing",
pages = "69--85",
booktitle = "Cancer Treatment and Research",

}

TY - CHAP

T1 - Biomarkers of cancer-associated thromboembolism

AU - Mahajan, Anjlee

AU - Wun, Theodore

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Venous thromboembolism is known to be associated with an increase in morbidity and mortality in patients with malignancy. Predictive laboratory biomarkers of venous thromboembolism (VTE) have long been sought after to improve outcomes and help guide clinical decision making. Previously studied biomarkers include C reactive protein (CRP), tissue factor expressing microparticles (TF MP), D-dimer, soluble P-selectin (sP-selectin), plasminogen activator inhibitor 1 (PAI-1), factor VIII, platelet count, and leukocyte counts. This chapter will focus on these possible biomarkers for cancer-associated thrombosis (CAT) with particular emphasis on the pathophysiology behind thrombosis formation as well as data from clinical studies in patients with malignancy. The incorporation of the above biomarkers into risk assessment tools to predict CAT will also be reviewed, as will risk factors for recurrent VTE in patients with malignancy. Further studies are ongoing to develop readily available biomarkers that can be incorporated into future risk assessment models with the goal of reducing morbidity and mortality due to cancer-associated thrombosis.

AB - Venous thromboembolism is known to be associated with an increase in morbidity and mortality in patients with malignancy. Predictive laboratory biomarkers of venous thromboembolism (VTE) have long been sought after to improve outcomes and help guide clinical decision making. Previously studied biomarkers include C reactive protein (CRP), tissue factor expressing microparticles (TF MP), D-dimer, soluble P-selectin (sP-selectin), plasminogen activator inhibitor 1 (PAI-1), factor VIII, platelet count, and leukocyte counts. This chapter will focus on these possible biomarkers for cancer-associated thrombosis (CAT) with particular emphasis on the pathophysiology behind thrombosis formation as well as data from clinical studies in patients with malignancy. The incorporation of the above biomarkers into risk assessment tools to predict CAT will also be reviewed, as will risk factors for recurrent VTE in patients with malignancy. Further studies are ongoing to develop readily available biomarkers that can be incorporated into future risk assessment models with the goal of reducing morbidity and mortality due to cancer-associated thrombosis.

KW - Biomarkers

KW - C reactive protein

KW - D-dimer

KW - Factor VIII

KW - P-selectin

KW - Tissue factor

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85069531580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069531580&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-20315-3_5

DO - 10.1007/978-3-030-20315-3_5

M3 - Chapter

C2 - 31317481

AN - SCOPUS:85069531580

T3 - Cancer Treatment and Research

SP - 69

EP - 85

BT - Cancer Treatment and Research

PB - Springer International Publishing

ER -